Mark Rogel specializes in patent matters pertaining to biotechnology. His practice includes US and international patent preparation and prosecution, freedom to operate and patentability analyses, and intellectual property due diligence. Mark has experience in a wide range of technologies, such as cellular and molecular biology, immunology, polypeptide and polynucleotide therapeutics, including RNAi and antisense therapeutics, therapeutic antibodies, recombinant vaccines, gene therapy, stem cell therapeutics, diagnostics, drug delivery systems, biological assay development, and biology-based clean energy.

Download full bio 


  • NantKwest – $238 Million IPO 

  • Five Prime Therapeutics IPO 


  • University of Washington School of Law
    JD, 2007

  • University of Washington
    BS, 1994

Admissions & Credentials


U.S. Patent and Trademark Office


  • Washington Biotechnology and Biomedical Association

  • Washington State Patent Law Association